Search

Background: Asthma epidemics associated with thunderstorms have had catastrophic effects on individuals and emergency services. Seasonal allergic rhinitis (SAR) is present in the vast majority of people who develop thunderstorm asthma (TA), but there is little evidence regarding risk factors for TA among the SAR population. Objective(s): We sought to identify risk factors for a history of TA and hospital presentation in a cohort of individuals with SAR. Method(s): This multicenter study recruited adults from Melbourne, Australia, with a past diagnosis of TA and/or self-reported SAR. Clinical information, spirometry results, white blood cell count, ryegrass pollen-specific (RGP-sp) IgE concentration, and fractional exhaled nitric oxide were measured to identify risk factors for a history of TA in individuals with SAR. Result(s): From a total of 228 individuals with SAR, 35% (80 of 228) reported SAR only (the I-SAR group), 37% (84 of 228) reported TA symptoms but had not attended hospital for treatment (the O-TA group), and 28% (64 of 228) had presented to the hospital for TA (the H-TA group). All patients in the H-TA group reported a previous asthma diagnosis. Logistic regression analysis of factors associated with O-TA and H-TA indicated that lower FEV1 value and an Asthma Control Questionnaire score higher than 1.5 were associated with H-TA. Higher blood RGP-sp IgE concentration, eosinophil counts, and fractional exhaled nitric oxide level were significantly associated with both O-TA and H-TA. Receiver operating curve analysis showed an RGP-sp IgE concentration higher than 10.1 kU/L and a prebronchodilator FEV1 value of 90% or lower to be biomarkers of increased H-TA risk. Conclusion(s): Clinical tests can identify risk of a history of TA in individuals with SAR and thereby inform patient-specific treatment recommendations.Copyright © 2021

Background: Asthma epidemics associated with thunderstorms have had catastrophic effects on individuals and emergency services. Seasonal allergic rhinitis (SAR) is present in the vast majority of people who develop thunderstorm asthma (TA), but there is little evidence regarding risk factors for TA among the SAR population. Objective(s): We sought to identify risk factors for a history of TA and hospital presentation in a cohort of individuals with SAR. Method(s): This multicenter study recruited adults from Melbourne, Australia, with a past diagnosis of TA and/or self-reported SAR. Clinical information, spirometry results, white blood cell count, ryegrass pollen-specific (RGP-sp) IgE concentration, and fractional exhaled nitric oxide were measured to identify risk factors for a history of TA in individuals with SAR. Result(s): From a total of 228 individuals with SAR, 35% (80 of 228) reported SAR only (the I-SAR group), 37% (84 of 228) reported TA symptoms but had not attended hospital for treatment (the O-TA group), and 28% (64 of 228) had presented to the hospital for TA (the H-TA group). All patients in the H-TA group reported a previous asthma diagnosis. Logistic regression analysis of factors associated with O-TA and H-TA indicated that lower FEV1 value and an Asthma Control Questionnaire score higher than 1.5 were associated with H-TA. Higher blood RGP-sp IgE concentration, eosinophil counts, and fractional exhaled nitric oxide level were significantly associated with both O-TA and H-TA. Receiver operating curve analysis showed an RGP-sp IgE concentration higher than 10.1 kU/L and a prebronchodilator FEV1 value of 90% or lower to be biomarkers of increased H-TA risk. Conclusion(s): Clinical tests can identify risk of a history of TA in individuals with SAR and thereby inform patient-specific treatment recommendations.Copyright © 2021

The 6-minute walk test (6MWT) is recommended to be performed twice to accurately assess exercise performance in stable chronic obstructive pulmonary disease (COPD) due to the presence of a learning effect. It is unknown whether a learning effect exists when the 6MWT is performed during hospitalisation for acute exacerbation of COPD (AECOPD). This study investigated whether repeat 6MWTs are necessary when conducted in inpatients with AECOPD. Pooled analysis was undertaken of data from two studies (Australia and Brazil) involving 46 participants (25 males, mean age 67.2 years, FEV1 43% predicted) admitted with AECOPD. Two 6MWTs, separated by >=20 minutes, were performed on the day of discharge. Six-minute walk distance (6MWD; primary outcome), perceived dyspnoea (Borg scale), heart rate and oxyhaemoglobin saturation were recorded. 6MWD data from tests one (T1) and two (T2) were analysed via visual inspection of Bland-Altman plots. Factors associated with test improvement or decline were explored. Mean 6MWD difference between T1 and T2 was 6.2 m, however limits of agreement were wide (-92.2 m to 104.5 m). 32 (70%) participants improved (by any distance) from T1 to T2 by a mean (+/- standard deviation) of 32 m +/- 28 m. Of these, 14 (30%) improved by a distance > 30 m. Fourteen (30%) participants recorded poorer 6MWD at T2 by a mean of 52 m +/- 36 m. No factors were able to identify participants who improved or declined upon repeat testing. When performed in patients admitted to hospital with AECOPD, the 6MWT needs to be conducted twice in order to better estimate 6MWD.Copyright © 2016 Taylor & Francis Group, LLC.

The 6-minute walk test (6MWT) is recommended to be performed twice to accurately assess exercise performance in stable chronic obstructive pulmonary disease (COPD) due to the presence of a learning effect. It is unknown whether a learning effect exists when the 6MWT is performed during hospitalisation for acute exacerbation of COPD (AECOPD). This study investigated whether repeat 6MWTs are necessary when conducted in inpatients with AECOPD. Pooled analysis was undertaken of data from two studies (Australia and Brazil) involving 46 participants (25 males, mean age 67.2 years, FEV1 43% predicted) admitted with AECOPD. Two 6MWTs, separated by >=20 minutes, were performed on the day of discharge. Six-minute walk distance (6MWD; primary outcome), perceived dyspnoea (Borg scale), heart rate and oxyhaemoglobin saturation were recorded. 6MWD data from tests one (T1) and two (T2) were analysed via visual inspection of Bland-Altman plots. Factors associated with test improvement or decline were explored. Mean 6MWD difference between T1 and T2 was 6.2 m, however limits of agreement were wide (-92.2 m to 104.5 m). 32 (70%) participants improved (by any distance) from T1 to T2 by a mean (+/- standard deviation) of 32 m +/- 28 m. Of these, 14 (30%) improved by a distance > 30 m. Fourteen (30%) participants recorded poorer 6MWD at T2 by a mean of 52 m +/- 36 m. No factors were able to identify participants who improved or declined upon repeat testing. When performed in patients admitted to hospital with AECOPD, the 6MWT needs to be conducted twice in order to better estimate 6MWD.Copyright © 2016 Taylor & Francis Group, LLC.

PURPOSE: Precise, inexpensive tools for measuring physical activity levels are important for developing strategies to improve symptoms and enhance quality of life in chronic obstructive pulmonary disease (COPD). Self-report questionnaires and diaries have been used in many populations with variable results. The pedometer is widely recognized as a valid and reliable objective measurement tool, but it has not been well tested in COPD. This study aimed to determine the relationship between free-living physical activity recorded in a daily diary and that measured by using a pedometer in patients with COPD. METHODS: Participants with COPD (n = 80) recorded physical activity over 7 days. Cumulative pedometer readings and diary records of 4 activity categories for each 0.5 hour were compared. RESULTS: Participants (n = 76) with complete data sets were included in the analysis. The diary was more reliably completed. Mean pedometer reading per week was 23,129 (SD = 17,083) "step" counts (range, 1,725-66,454). Mean diary-recorded standing and walking time per week was 98.9 (SD = 10.4) hours (range, 73-119.5). The relationship between these measures was moderate and statistically significant (r = 0.37, P = .001). CONCLUSIONS: A daily diary record appears to offer more promise than the pedometer as a tool for measuring free-living physical activity in patients with COPD. Further research is required to assess the value of the 2 methods as discriminative, evaluative, and predictive tools in COPD populations.

PURPOSE: Precise, inexpensive tools for measuring physical activity levels are important for developing strategies to improve symptoms and enhance quality of life in chronic obstructive pulmonary disease (COPD). Self-report questionnaires and diaries have been used in many populations with variable results. The pedometer is widely recognized as a valid and reliable objective measurement tool, but it has not been well tested in COPD. This study aimed to determine the relationship between free-living physical activity recorded in a daily diary and that measured by using a pedometer in patients with COPD. METHODS: Participants with COPD (n = 80) recorded physical activity over 7 days. Cumulative pedometer readings and diary records of 4 activity categories for each 0.5 hour were compared. RESULTS: Participants (n = 76) with complete data sets were included in the analysis. The diary was more reliably completed. Mean pedometer reading per week was 23,129 (SD = 17,083) "step" counts (range, 1,725-66,454). Mean diary-recorded standing and walking time per week was 98.9 (SD = 10.4) hours (range, 73-119.5). The relationship between these measures was moderate and statistically significant (r = 0.37, P = .001). CONCLUSIONS: A daily diary record appears to offer more promise than the pedometer as a tool for measuring free-living physical activity in patients with COPD. Further research is required to assess the value of the 2 methods as discriminative, evaluative, and predictive tools in COPD populations.